About Broad Street Alerts:
Note*** We are issuing breakout watch on (NYSE-MKT: FSI)
Big opportunities in Small Cap’s in a down market
Broadstreetalerts.com recent profiles and track record, 157% in verifiable potential gains for our members in December 2015 alone.
December 29th, 2015- (NASDAQ: INVT) opened $1.35/share hit a high midday of $2.82/share over 100% in gains for our members.
December 15th, 2015-(NYSE-MKT: XXII) opened at $1.29 hit a high of $1.54 within 3 days for gains of 19% for our members.
December 2nd, 2015- (NASDAQ: TCCO) opened at $3.25 hit a high of $4.50 within 3 days for 38% gains for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business. We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Due Diligence Report: Commencement of Clinical Trials Sends ARTH Soaring
Summary:
Arch Therapeutics, Inc. (Arch), incorporated on September 16, 2009, is a life science medical device company. Arch is a biotechnology company, which is focused on developing an approach for the cessation of bleeding (hemostasis) and control of fluid leakage (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids. Arch Biosurgery, Inc. is a subsidiary of the Company.
The Company’s products are in preclinical development. Its development-stage product, AC5 Surgical Hemostatic Device (AC5), is designed to achieve hemostasis in minimally invasive and open surgical procedures. AC5 is designed to be a biocompatible synthetic peptide that consists of naturally occurring amino acids and used for direct application as a liquid. When applied to a wound, AC5 intercalates into the interstices of the connective tissue where it self-assembles into a physical, mechanical structure that provides a barrier to leaking substances, such as blood. It conforms to irregular wound geometry, allows for normal healing, and helps maintain a clear field of vision. AC5 is a clear transparent gel that enables doctors to see through it as they work, performing Crystal Clear Surgery. The Company is focused on conducting its human clinical trial of AC5, a randomized controlled single-blind investigation, which is designed to assess safety and performance of AC5 in bleeding wounds created during the course of a dermatological procedure in approximately 50 patients. The Company is in the development stage, has not generated any revenues.
Arch Therapeutics, Inc. has a current market capitalization of $23.89 M with 109.57 M outstanding shares. Its daily average volume traded is 151,008 shares.
Financial Highlights (Q3 2015):
Revenue: Nil
Gross Profit: Nil
Net Income: -1.16M
Cash and Cash Equivalents: 2.82 M
Total Debt: 1.24 M
Recent News and Analysis:
The company recently announced that it has initiated patient enrollment and treatment in its first clinical trial in Western Europe. The randomized controlled single-blind investigation is designed to assess safety and performance of AC5 during the course of a dermatological procedure performed in up to approximately 45 patients, of whom 10 will be taking an antiplatelet medication (commonly referred to as a “blood thinner”) during the study period. Patients participating in the study will have at least two dermatological lesions removed surgically. One of the wounds created as a result of the excision will receive AC5 while the other will receive a control treatment. The endpoints include product related adverse effects and time to hemostasis. Follow-up assessments of patients are planned for seven and 30 days following the procedure. As previously stated, data are projected to be available within two quarters of the start of the trial.
Dr. Norchi, President and CEO of Arch said, “This clinical trial is a key component of our commercialization plan, representing the first time that AC5 has been used on humans in a surgical setting. Further, it highlights that Arch has completed a number of important achievements that are required before a patient could be treated with AC5. As we are getting closer to bringing AC5 to market, we continue to advance our pre-clinical work and clinical-regulatory planning for additional indications for AC5 and other products, in each case with the ultimate goal of making a difference in patients’ lives.”
Conclusions:
Entering the clinical trials sent the stock up 14.5% mid-day Monday as investors hope for positive results from these trials in the quarters to come. With the mindset that entering into a position early will pay off, the stock doubled its daily average of shares traded by mid-day Monday and has tested and held above its 20 day SMA all morning. Investors should watch for whether it closes and above the 20 day SMA to strengthen the trend reversal into the positive, upward direction. As always, perform your due diligence before investing in stocks, especially small caps.
Sources:
- http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=ARTH.OB
- https://www.google.ca/finance?q=OTCBB%3AARTH&fstype=ii&hl=en&gl=ca&ei=Jq7dVuzQO9f3jAHklKf4DA
- http://finance.yahoo.com/q?s=ARTH&ql=0
- http://finance.yahoo.com/news/arch-therapeutics-clinical-trial-actively-125700915.html
Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it, and I have no business relationship with any company whose stock is mentioned in the article. I reserve the right to sell the redistribution rights to this report for up to two hundred fifty dollars/news source.
The information contained herein is not intended to be investment advice and does not constitute any form of invitation or inducement by Robert Borowski, MSc. to engage in investment activity. Neither the information nor any opinion expressed constitutes a solicitation for the purchase or sale of any security. Securities, financial instruments, strategies, or commentary mentioned herein may not be suitable for all investors and this material is not intended for any specific investor and does not take into account an investor’s particular investment objectives, financial situations or needs. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only current as of the stated date of their issue. Prices, values, or income from any securities or investments mentioned in this report may fluctuate, and an investor may, upon selling an investment lose a portion of, or the entire principal amount invested. Past performance is no guarantee of future results. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.
DISCLAIMER
Broad Street Alerts has compensated the author of this report up to two hundred and fifty dollars for the redistribution rights for a period of up to 30 days.
BroadStreetAlerts.com is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. We have not been compensated in any form by any entity for this report. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. SCS LLC is not a Broker/Dealer and does not engage in high frequency trading.
